[go: up one dir, main page]

CY1111118T1 - Αναλογα απολιποπρωτεϊνης (apolipoprotein) - Google Patents

Αναλογα απολιποπρωτεϊνης (apolipoprotein)

Info

Publication number
CY1111118T1
CY1111118T1 CY20101101089T CY101101089T CY1111118T1 CY 1111118 T1 CY1111118 T1 CY 1111118T1 CY 20101101089 T CY20101101089 T CY 20101101089T CY 101101089 T CY101101089 T CY 101101089T CY 1111118 T1 CY1111118 T1 CY 1111118T1
Authority
CY
Cyprus
Prior art keywords
apolipoprotein
construct
potent
apolipoprotein construct
apo
Prior art date
Application number
CY20101101089T
Other languages
English (en)
Inventor
Jonas Graversen
S Ren Moestrup
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1111118T1 publication Critical patent/CY1111118T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση σχετίζεται με μία κατασκευή απολιποπρωτεΐνης(apolipoprotein), μία κατασκευή απολιποπρωτεΐνης (apolipoprotein) για χρήση σαν φαρμάκου, μία αλυσίδα νουκλεϊκού (nucleic) οξέος που κωδικοποιεί την κατασκευή απολιποπρωτεΐνης (apolipoprotein), ένα φορέα που περιλαμβάνει την αλυσίδα νουκλεϊκού (nucleic) οξέος, μία μέθοδο για την παραγωγή της κατασκευής απολιποπρωτεΐνης (apolipoprotein), και την χρήση της κατασκευής απολιποπρωτεΐνης (apolipoprotein) για την παρασκευή μιας φαρμακευτικής σύνθεσης. Τα δεδομένα που παρουσιάζονται τεκμηριώνουν ότι η κατασκευή σύμφωνα με την εφεύρεση είναι ικανή να συνδέσει λιπίδια, είναι ικανή να συνδέσει την cubilin, πού είναι ένας ισχυρός λήπτης Αpο Αl, ισχυρότερος από την γηγενή Αpο Α-I και ότι η διάρκεια μισής ζωής στο πλάσμα των κατασκευών είναι τουλάχιστον τριπλάσια σε σύγκριση με την γηγενή Αpο Α-Ι. Μαζί αυτά τα δεδομένα τεκμηριώνουν ότι οι κατασκευές σύμφωνα με την εφεύρεση είναι ισχυροί υποψήφιοι για την θεραπεία καρδιαγγειακών ασθενειών.
CY20101101089T 2000-11-10 2010-11-29 Αναλογα απολιποπρωτεϊνης (apolipoprotein) CY1111118T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200001682 2000-11-10
DKPA200100057 2001-01-15
US26402201P 2001-01-26 2001-01-26
EP01982197A EP1335938B1 (en) 2000-11-10 2001-11-09 Apolipoprotein construct

Publications (1)

Publication Number Publication Date
CY1111118T1 true CY1111118T1 (el) 2015-06-11

Family

ID=27222453

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101089T CY1111118T1 (el) 2000-11-10 2010-11-29 Αναλογα απολιποπρωτεϊνης (apolipoprotein)

Country Status (10)

Country Link
US (4) US6897039B2 (el)
EP (2) EP1335938B1 (el)
JP (2) JP4344136B2 (el)
CN (1) CN1268641C (el)
AU (2) AU2002213843B2 (el)
BR (1) BR0115257A (el)
CA (1) CA2428114C (el)
CY (1) CY1111118T1 (el)
NO (1) NO331274B1 (el)
WO (1) WO2002038609A2 (el)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
EP1353666B1 (en) 2001-01-02 2013-07-03 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
NZ532217A (en) * 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
WO2004069795A2 (en) * 2003-02-03 2004-08-19 Pfizer Products Inc. Diagnosis and treatment of chronic tissue damage
AU2004212944B2 (en) * 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
AU2004223829A1 (en) * 2003-03-24 2004-10-07 Sequoia Pharmaceuticals, Inc. Long acting biologically active conjugates
CL2004000858A1 (es) * 2003-04-22 2005-04-22 Avanir Pharmaceuticals Peptidos que comprende una region acida, una lipofilica o aromatica y una basica, que participan en transporte inverso de colesterol, composicion farmaceutica que los contienen, util para el tratamiento o prevencion de hipercolesterolemia y/o aterosc
JP4833056B2 (ja) 2003-04-23 2011-12-07 アナフォア インコーポレイテッド グランザイムｂプロテアーゼを使用した融合タンパク質の開裂
US7459286B1 (en) 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
EP1697746B1 (en) 2003-12-05 2012-02-22 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050176623A1 (en) * 2004-02-11 2005-08-11 Neil Wagle Non-invasive treatment of disease using amphipathic compounds
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006020498A2 (en) * 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US20070048823A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics, S.A. Compositions and Methods for Producing Apolipoprotein Gene Products in Lactic Acid Bacteria
US20080248565A1 (en) * 2007-03-01 2008-10-09 Invitrogen Corporation Isolated phospholipid-protein particles
US20070117179A1 (en) * 2005-09-27 2007-05-24 Invitrogen Corporation In vitro protein synthesis systems for membrane proteins that include adolipoproteins and phospholipid-adolipoprotein particles
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
EP2140874A4 (en) * 2007-04-23 2010-10-20 Nihon Pharmaceutical Co Ltd FOR THE TREATMENT OF ACUTE HEPATITIS OR FOR THE PREVENTION / TREATMENT OF FULMINATE HEPATITIS
EP2195337A1 (en) * 2007-10-08 2010-06-16 Anaphore, Inc. Trimeric il-1ra
US8999320B2 (en) * 2008-01-30 2015-04-07 The Rockefeller University Nanoscale bound bilayers, methods of use and production
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
WO2010057203A2 (en) * 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
US20120157380A1 (en) * 2009-06-05 2012-06-21 Nan Wang Pegylated human apoa-1 and process for production thereof
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
RU2597989C2 (ru) * 2009-12-11 2016-09-20 Проекто Де Биомедисина Сима С.Л. Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
EP2582379A4 (en) * 2010-06-15 2013-12-04 Matthew C Lawyer COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS
CN101923093B (zh) * 2010-07-13 2013-12-18 昆明理工大学 树鼩IgG的三抗体夹心ELISA检测方法
KR20130117760A (ko) * 2010-08-30 2013-10-28 에프. 호프만-라 로슈 아게 테트라넥틴-아포지단백질 a-i 입자의 제조 방법, 이에 의해 제조된 지질 입자 및 이의 용도
US9187550B2 (en) * 2010-08-30 2015-11-17 Hoffman—La Roche Inc. Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
EP2611900B1 (en) * 2010-08-30 2015-11-25 F.Hoffmann-La Roche Ag Alkaline feed
US20120190609A1 (en) * 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
JP2013535978A (ja) * 2010-08-30 2013-09-19 エフ．ホフマン−ラ ロシュ アーゲー 原核生物における発現構築物
CA2807433A1 (en) * 2010-08-30 2012-03-08 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
CN103443123B (zh) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
JP6116565B2 (ja) * 2011-08-25 2017-04-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 陽イオンおよび陰イオン交換クロマトグラフィー法
KR20140054115A (ko) * 2011-08-25 2014-05-08 에프. 호프만-라 로슈 아게 단축 테트라넥틴-아포지단백질 a-i 융합 단백질, 그를 함유하는 지질 입자 및 그의 용도
US20140378376A1 (en) * 2011-12-21 2014-12-25 Csl Limited Dosage Regime for Apolipoprotein Formulations
KR101536037B1 (ko) * 2012-02-24 2015-07-13 성균관대학교산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
WO2013125769A1 (ko) * 2012-02-24 2013-08-29 성균관대학교 산학협력단 아포리포단백질을 포함하는 항체-약물 결합체
EA201491898A1 (ru) 2012-04-19 2015-08-31 Опко Байолоджикс Лтд. Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
WO2014023315A1 (en) * 2012-08-10 2014-02-13 Aarhus Universitet Multimerization through beta-strand swapping in ccp domains
EP3848386A1 (en) 2012-11-20 2021-07-14 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
KR102275477B1 (ko) * 2013-06-05 2021-07-13 시에스엘 리미티드 아포지단백질 Ａ―Ｉ（Ａｐｏ Ａ―Ｉ）의 제조방법
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
US10961286B2 (en) 2014-08-15 2021-03-30 Cornell University Nucleic acids, vectors, host cells, and methods for recombinantly producing water-soluble membrane proteins
RU2743295C2 (ru) 2014-12-10 2021-02-16 Опко Байолоджикс Лтд. Способы производства стр-модифицированных полипептидов гормона роста длительного действия
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA2997263C (en) 2015-09-08 2022-10-04 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2018136163A2 (en) * 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
US20190046608A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Apomers
WO2019048871A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol PROTEIN ADMINISTRATION TO MEMBRANES
EP4135747A1 (en) 2020-04-16 2023-02-22 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN114940711B (zh) * 2021-10-25 2023-05-12 中山大学 载脂蛋白a-i模拟肽及其应用
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
CN119384269A (zh) 2022-04-06 2025-01-28 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗眼病的方法
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
AU2023285382A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
CN115290776A (zh) * 2022-07-26 2022-11-04 云南大学 瘤牛锥虫病抗性蛋白的应用
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025175130A1 (en) * 2024-02-16 2025-08-21 The Children's Medical Center Corporation Apom fusion constructs and methods of use in treating inflammatory diseases
CN119823289B (zh) * 2025-03-20 2025-06-10 内蒙古和讯生物科技有限公司 一种蛋白基生物材料及其制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5068045A (en) * 1985-08-27 1991-11-26 Mobil Oil Corporation Grease composition containing alkoxylated amide borates
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) * 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5177189A (en) * 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
WO1992009893A1 (en) * 1990-11-29 1992-06-11 Carbaugh John E DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a)
EP0590060B1 (en) 1991-06-21 1997-09-17 University Of Cincinnati Orally administrable therapeutic proteins and method of making
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1994004563A1 (fr) * 1992-08-14 1994-03-03 Shino-Test Corporation PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
EP0603992B2 (en) 1992-12-22 2000-12-06 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
CA2155335C (en) 1993-02-04 2001-06-05 HANS CHRISTIAN THõGERSEN Improved method for the refolding of proteins
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
JP3628333B2 (ja) * 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
DE69827507T2 (de) 1997-06-11 2006-03-09 Borean Pharma A/S Trimerisierendes modul
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis

Also Published As

Publication number Publication date
JP4344136B2 (ja) 2009-10-14
JP2009118849A (ja) 2009-06-04
NO331274B1 (no) 2011-11-14
JP2004522424A (ja) 2004-07-29
NO20032101L (no) 2003-07-08
US6897039B2 (en) 2005-05-24
CN1486327A (zh) 2004-03-31
WO2002038609A3 (en) 2002-09-26
NO20032101D0 (no) 2003-05-09
BR0115257A (pt) 2003-08-12
WO2002038609A2 (en) 2002-05-16
US20050142639A1 (en) 2005-06-30
US20050096277A1 (en) 2005-05-05
CN1268641C (zh) 2006-08-09
CA2428114A1 (en) 2002-05-16
US20090136467A1 (en) 2009-05-28
AU1384302A (en) 2002-05-21
EP1335938B1 (en) 2010-09-22
CA2428114C (en) 2013-07-23
US20020156007A1 (en) 2002-10-24
AU2002213843A2 (en) 2002-05-21
EP1335938A2 (en) 2003-08-20
AU2002213843B2 (en) 2008-02-07
EP2343317A1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
CY1111118T1 (el) Αναλογα απολιποπρωτεϊνης (apolipoprotein)
CY1109439T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
FI965201A0 (fi) Puhdistetut Polyporus-lakkaasit ja niitä koodaavat nukleiinihapot
DE69940264D1 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
FI964808A0 (fi) Puhdistetut Myceliophthora lakkaasit ja niitä koodaavat nukleiinihapot
CY1108407T1 (el) Τριαμιδο-υποκατεστημενες ινδολες, βενζοφουρανια και βενζοθειοφαινεια ως αναστολεις της μικροσωμιακης πρωτεϊνης μεταφορας τριγλυκεριδιων (mtp) και/ή της εκκρισης απολιποπρωτεϊνης β (αρο β)
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
DE60034566D1 (de) Peptidakzeptor ligationsverfahren
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
CY1111099T1 (el) Στελεχη ζυμης τα οποια παραγουν στεροειδη με αυτονομο τροπο
CY1111991T1 (el) Glp-1 αναλογα πρωτεϊνων συντηξης
BRPI0413973A (pt) compostos
CY1112654T1 (el) Διαμορφομερη βακτηριακων προσκολλητινων
CY1112735T1 (el) Πολυπεπτιδια δυναμενα εκμαιευσης μιας ανοσιακης αντιδρασης εναντι του καρκινου
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
WO2003018756A3 (en) Methods for preparing purified prostaglandin e synthase
CY1105012T1 (el) Επικαλυψη, διαδικασια παρασκευης και χρηση της σε τεμαχια απο ξυλο
DE502004009136D1 (de) NEUE HETEROARYLSUBSTITUIERTE ACETONDERIVATE ALS HEMMSTOFFE DER PHOSPHOLIPASE A sb 2 /sb
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DK573886D0 (da) Fremgangsmaade til fremstilling af beskyttede argininholdige peptider
DE69935785D1 (de) Substitutierte aminosaeuren als erythropoietin-mimetica
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας
CY1105405T1 (el) Dna και πολυπεπτιδια il-1ζ, παραλλαγων ματισματος il-1ζ και xrec2